NEWTON, Mass.--(BUSINESS WIRE)--PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), today announced that it has established a research collaboration with Antonino Musolino, M.D., and the Azienda Ospedaliero – Universitaria di Parma (University Hospital of Parma), Italy, to validate the use of genetic variants in the FCGR pathways in predicting response to trastuzumab (Herceptin) therapy in patients with breast cancer. The research will include an international prospective trial to evaluate the association of genetic variants, such as the FCGR3A F158V genotype, with response to trastuzumab in breast cancer treatment. The collaboration expands PGxHealth’s FCGR (Fc gamma receptor) program that includes its PGxPredict®:RITUXIMAB test for a gene variant used to determine response to rituximab monotherapy in follicular non-Hodgkin’s lymphoma.
